EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Abnormal Tau Phosphorylation for Alzheimer’s Therapeutics

Aditya Singh, Vaseem Ahamad Ansari, Tarique Mahmood, Syed Misbahul Hasan, Rufaida Wasim, Shubhrat Maheshwari, Juber Akhtar, Suvaiv Sheikh, Vishal Kumar Vishwakarma

Hormone and Metabolic Research · 2024-07 · 56 (07) · 482-488

DOI: 10.1055/a-2238-1384 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hormone and Metabolic Research, online erschienen am 13.02.2024. Verfasst von Aditya Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Integral University, Lucknow, India. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a widespread neurodegenerative disorder characterized by progressive memory and cognitive decline, posing a formidable public health challenge. This review explores the intricate interplay between two pivotal players in AD pathogenesis: β-amyloid (Aβ) and tau protein. While the amyloid cascade theory has long dominated AD research, recent developments have ignited debates about its centrality. Aβ plaques and tau NFTs are hallmark pathologies in AD. Aducanumab and lecanemab, monoclonal antibodies targeting Aβ, have been approved, albeit amidst controversy, raising questions about the therapeutic efficacy of Aβ-focused interventions. On the other hand, tau, specifically its hyperphosphorylation, disrupts microtubule stability and contributes to neuronal dysfunction. Various post-translational modifications of tau drive its aggregation into NFTs. Emerging treatments targeting tau, such as GSK-3β and CDK5 inhibitors, have shown promise in preclinical and clinical studies. Restoring the equilibrium between protein kinases and phosphatases, notably protein phosphatase-2A (PP2A), is a promising avenue for AD therapy, as tau is primarily regulated by its phosphorylation state. Activation of tau-specific phosphatases offers potential for mitigating tau pathology. The evolving landscape of AD drug development emphasizes tau-centric therapies and reevaluation of the amyloid cascade hypothesis. Additionally, exploring the role of neuroinflammation and its interaction with tau pathology present promising research directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsHumansPhosphorylationAnimalsAmyloid beta-Peptides

Substanzen

tau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Faculty of Pharmacy, Integral University, Lucknow, India.
  • Faculty of Pharmaceutical Sciences, Rama University, Kanpur, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.

Zitieren

APA

Singh, A., Ansari, V. A., Mahmood, T., Hasan, S. M., Wasim, R., Maheshwari, S., Akhtar, J., Sheikh, S., & Vishwakarma, V. K. (2024). Targeting Abnormal Tau Phosphorylation for Alzheimer’s Therapeutics. Hormone and Metabolic Research, 56(07), 482-488. https://doi.org/10.1055/a-2238-1384

Vancouver

Singh A, Ansari VA, Mahmood T, Hasan SM, Wasim R, Maheshwari S, et al. Targeting Abnormal Tau Phosphorylation for Alzheimer’s Therapeutics. Hormone and Metabolic Research. 2024;56(07):482-488. doi:10.1055/a-2238-1384

BibTeX
@article{Singh2024,
  author = {Singh, Aditya and Ansari, Vaseem Ahamad and Mahmood, Tarique and Hasan, Syed Misbahul and Wasim, Rufaida and Maheshwari, Shubhrat and Akhtar, Juber and Sheikh, Suvaiv and Vishwakarma, Vishal Kumar},
  title = {Targeting Abnormal Tau Phosphorylation for Alzheimer’s Therapeutics},
  journal = {Hormone and Metabolic Research},
  year = {2024},
  volume = {56},
  number = {07},
  pages = {482--488},
  doi = {10.1055/a-2238-1384}
}
Kostenlos starten →